Collagen Solutions PLC Appointment of Chief Business Officer

TIDMCOS

Collagen Solutions PLC

10 April 2018

10 April 2018

Collagen Solutions plc

("Collagen Solutions" or the "Company")

Appointment of Chief Business Officer

Collagen Solutions Plc (AIM: COS), the developer and manufacturer of biomaterials for the enhancement and extension of human life, announces the appointment of Louis T. Ruggiero ("Lou") as Chief Business Officer effective as of 16 April 2018.

Collagen Solutions recently completed a comprehensive business review with the help of Mr. Ruggiero, including a review of the Company's commercial operations and organisation. During this process, Mr. Ruggiero developed a solid understanding of the Company's opportunity for growth and path to execution, as well as the confidence of the executive team and Board as a strong commercial leader.

Mr. Ruggiero is a performance-driven executive with proven success at all levels of sales and general management in the health care and technology industries. He joins Collagen Solutions from Pearson Clinical Assessments where he served as Senior Vice President of Sales. Previously, Mr. Ruggiero spent 10 years as a senior executive and Board Director in the orthopedic device industry. Under his leadership as Chief Commercial Officer of Hely & Weber Orthopedics and Ossur Americas, the companies posted consistent double-digit revenue growth. As the Chief Sales & Marketing Officer of DJO Global, revenue and share price increased over five-fold. Earlier in his career, Mr. Ruggiero served as CEO of Titan Scan Technologies, an early stage B2B company focused on medical device sterilisation and bio-agent remediation. In addition, Mr. Ruggiero served in various leadership roles of increasing responsibility with GE Healthcare, where he earned his Six Sigma Certification.

Mr. Ruggiero is a summa cum laude graduate of St. John's University, where he majored in Interpersonal Communication and Political Science, and earned an MBA from Northwestern University Kellogg Graduate School of Management. He is also completing a Doctoral degree in Organizational Leadership from Creighton University.

On joining Collagen Solutions, Mr. Ruggiero said: "I was attracted by the Company's mission and the passionate commitment that Jamal and the Board has to grow the business. I believe that Collagen Solutions is well positioned to strengthen and accelerate its core business, while fueling further revenue growth through the sale of its proprietary products."

Jamal Rushdy, CEO of Collagen Solutions, added: "I am excited to work with Lou again, having previously worked together at DJO through a period of significant organic and acquired growth. Lou's commercial successes in multiple healthcare and B2B organisations stem from his proven ability to build strong teams, lead with a level of passion, accountability, and creativity, and drive aggressive revenue growth. I have great confidence that Lou's appointment will accelerate our commercial opportunities and look forward to partnering with him to realise our vision to be the industry's first choice for regenerative biomaterials."

End

 
  Collagen Solutions Plc                        Tel: [phone] 
   Jamal Rushdy, Chief Executive Officer 
   Hilary Spence, Chief Financial Officer 
   Lisa Baderoon, Head of Investor Relations     Tel: [phone] or [e-mail] 
  Cenkos Securities plc (NOMAD and Broker)      Tel: [phone] 
   Stephen Keys 
   Steve Cox 
  Walbrook PR                                   Tel: [phone] or [e-mail] 
   Anna Dunphy                                   Mob: [phone] 
   Helen Cresswell 
 

About Collagen Solutions:

Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic(R). The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.

For more information go to: www.collagensolutions.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRASSIFLUFASELL

(END) Dow Jones Newswires

April 10, 2018 02:01 ET (06:01 GMT)